Trials / Conditions / Tyrosine Kinase Inhibitor

Tyrosine Kinase Inhibitor

17 registered clinical trials studyying Tyrosine Kinase Inhibitor — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Pa NCT07061145	Azienda USL Reggio Emilia - IRCCS	—
Recruiting	Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal M NCT07092202	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Phase 4
Not Yet Recruiting	SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcino NCT06538935	Fujian Cancer Hospital	Phase 2
Not Yet Recruiting	Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatmen NCT06662877	Sun Yat-sen University	Phase 2 / Phase 3
Recruiting	Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-adv NCT06755684	Peng Zhang	Phase 2
Not Yet Recruiting	Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL NCT06658925	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Active Not Recruiting	HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC NCT06632106	First Hospital of China Medical University	—
Unknown	HRQOL in Locally Advanced Thyroid Carcinoma NCT05824312	Fujian Cancer Hospital	—
Unknown	Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitor in Patients With Chronic Myeloid Leukemia NCT05259228	National Taiwan University Hospital	—
Completed	Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation NCT05263947	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Active Not Recruiting	Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166	Wenjun Cheng	Phase 2
Completed	The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein NCT04997850	Xinrui Zhu，MD	Phase 1 / Phase 2
Completed	Oncotool for Cancer Medications NCT03952312	Northwestern University	N/A
Completed	Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Facto NCT03996096	University Hospital, Caen	—
Unknown	Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-tran NCT03624530	Nanfang Hospital, Southern Medical University	Phase 2 / Phase 3
Recruiting	ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI) NCT05221372	Erasmus Medical Center	—
Completed	Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplant NCT07418138	Hu Liangshuo	—